Loading stock data…
Alvotech (ALVO)
$3.06-0.12 (-3.77%)
Market ClosedLast close Jul 24
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alvotech in the Healthcare sector is trading at $3.06 with a market capitalization of $1.3B. Wall Street consensus targets $6.50 (5 analysts), implying a +112.4% move over the next 12 months. The stock is currently near its 52-week low of $2.94, remaining 33.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +112.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105.86M↓ | $166.57M↑ | $113.74M↓ | $173.24M↑ | $132.76M |
| Gross Profit | $59.78M↓ | $105.29M↑ | $78.74M↓ | $99.41M↑ | $67.32M |
| Operating Income | $9.67M↓ | $48.26M↑ | $1.31M↓ | $18.06M↑ | $10.58M |
| Net Income | $1.03M↑ | -$108.55M↓ | -$5.25M↓ | $32.04M↓ | $109.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.60%
Volume
Today's trading volume
577,585
Recent News
Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering
Alvotech stock is coming off a difficult stretch, with the share price down about 64% over the past five years, yet the broader valuation checks currently lean toward the shares looking cheap on several measures. Over the last five years, Alvotech has declined 63.7%, which puts the recent valuation signals into sharper focus for long term investors. On the one hand, fresh capital raises and progress in the biosimilar pipeline, including the US$125m public offering and FDA review of AVT16,...
Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)
Alvotech recently amended its credit agreement to add a new US$75 million term loan facility led by GoldenTree Asset Management, following a US$165 million equity raise in June 2026, giving the company access to US$240 million in additional capital to fund its biosimilar pipeline, product launches and global expansion. This fresh mix of debt and equity funding reshapes Alvotech’s balance sheet and could influence how investors view its ability to execute its growth plans. We’ll now examine...
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Fed Chair Warsh's International Debut
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2%, and the actively t
Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential
Alvotech (NASDAQ:ALVO) is one of the penny stocks with explosive growth potential. On June 18, Alvotech closed its underwritten public offering of 26,066,667 ordinary shares at $3.75 per share, raising ~$98 million in gross proceeds. This figure includes the full exercise of the underwriters’ option to purchase additional shares. The offering is complemented by a […]
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Fed Policy Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.04%, and the actively tr